CAN
ALNY icon

Cetera Advisor Networks’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cetera Advisor Networks’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,220
Closed -$234K – 2812
2023
Q4 		$234K Sell
1,220
-185
-13% -$31.5K ﹤0.01% 2417
2023
Q3 		$249K Sell
1,405
-77
-5% -$14.7K ﹤0.01% 2271
2023
Q2 		$281K Sell
1,482
-165
-10% -$32.7K ﹤0.01% 2128
2023
Q1 		$330K Buy
1,647
+9
+0.5% +$1.89K ﹤0.01% 1990
2022
Q4 		$389K Buy
+1,638
New +$349K ﹤0.01% 1816
2022
Q3 		– Sell
-4,853
Closed -$708K – 2092
2022
Q2 		$708K Buy
4,853
+554
+13% +$78.6K 0.01% 1062
2022
Q1 		$702K Buy
4,299
+1,313
+44% +$200K 0.01% 1102
2021
Q4 		$506K Buy
2,986
+225
+8% +$41.8K 0.01% 1273
2021
Q3 		$521K Buy
2,761
+696
+34% +$131K 0.01% 1201
2021
Q2 		$350K Buy
+2,065
New +$302K ﹤0.01% 1396

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cetera Advisor Networks's ALNY Position: Q1 2024 in Review

Cetera Advisor Networks sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 1,220 shares — an estimated $234K sold.

Cetera Advisor Networks first reported a position in ALNY in Q2 2021 and held it in 10 quarters. The position peaked at $708K in Q2 2022. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Cetera Advisor Networks reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cetera Advisor Networks sold 1,220 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $234K.
  • Cetera Advisor Networks first reported a position in Alnylam Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • Cetera Advisor Networks's Alnylam Pharmaceuticals position peaked at $708K in Q2 2022.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Cetera Advisor Networks's 13F filing for Q1 2024, filed 15 May 2024.